Symptom-based controller therapy: A new paradigm for asthma management

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Appropriate management of persistent asthma, according to US and international guidelines, requires daily use of controller medications, most generally, inhaled corticosteroids (ICS). This approach, although effective and well established, imposes burdens of treatment and side effects onto asthma patients. A growing body of evidence suggests that patients with persistent asthma need not be managed with daily ICS, but rather can use them on an intermittent basis, occasioned by the occurrence of symptoms sufficient to warrant treatment with a rescue inhaler. Large, randomized, controlled studies, over a range of asthma severity, and in a range of ages from pediatrics to adults, suggest that, in well-selected patients, a symptom-based approach to administering controller therapy may produce equivalent outcomes, while reducing exposure to ICS. The concept of providing anti-inflammatory treatment to the patient, at the time inflammation is developing, is termed 'temporal personalization'. The evidence to date suggests that symptom-based controller therapy is broadly useful in selected asthma patients, and is a management approach that could be incorporated into US and international guidelines for asthma.

Original languageEnglish (US)
Pages (from-to)427-433
Number of pages7
JournalCurrent Allergy and Asthma Reports
Issue number5
StatePublished - Oct 2013


  • Asthma
  • Inhaled corticosteroids
  • Management
  • Symptom-based controller therapy
  • Treatment

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Symptom-based controller therapy: A new paradigm for asthma management'. Together they form a unique fingerprint.

Cite this